Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.40 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a commitment to its ongoing clinical trials. However, they did not provide any updates on future guidance, which may have contributed to investor caution.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs.
Kodiak Sciences reported a loss per share of $0.40, but did not provide revenue figures or future guidance. The stock reacted negatively, declining by 0.75%. The lack of specific guidance may have raised concerns among investors about the company's near-term prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OLLIES BARGAIN OUTLE
Mar 26, 2019